Business
Easton Pharmaceuticals Announces Update to Its Cancer Drug Initiative: Majority Acquisition, Patent Strategy and Clinical Development Along With New Partnership Proposal Involving Medicinal Marijuana Drug Development
Easton Pharmaceuticals Announces Update to Its Cancer Drug Initiative: Majority Acquisition, Patent Strategy and Clinical Development Along With New Partnership Proposal Involving Medicinal Marijuana Drug Development.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals Announces Update to Its Cancer Drug Initiative: Majority Acquisition, Patent Strategy and Clinical Development Along With New Partnership Proposal Involving Medicinal Marijuana Drug Development\n \n \nEaston Pharmaceuticals Announces Update to Its Cancer Drug Initiative: Majority Acquisition, Patent Strategy and Clinical Development Along With New Partnership Proposal Involving Medicinal Marijuana Drug Development\n \n TORONTO, ON--(Marketwired - Mar 25, 2014) - Easton Pharmaceuticals, Inc. (OTC: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic / cosmetic healthcare products, announces it has entered into an agreement towards securing majority control of the cancer drug Xilive, pending certain conditions and a new partnership proposal towards medicinal marijuana. \n Easton is moving forward on its cancer drug Xilive based on the encouraging survival and disease-free data from two late-stage, long-term cancer survivors who have been on Xilive for several years each. Easton has closed on a majority ownership agreement with the inventor and current majority owners of the drug, but is conditional upon receiving clarification that the drug is patentable. Once the company receives confirmation, Easton will then close on its agreement to dramatically increase and gain a majority ownership position in Xilive with terms involving the issuance of common shares in the company, following which the company will proceed to focus on Xilive's development, formalize and strengthen the patent estate and announce specifics on its clinical development plan. Easton is able to disclose it has had preliminary talks with several well respected clinical investigators and CRO companies including with current advisors and consultants to the company with experience in cancer drug development, and intends to pursue their participation in Xilive's clinical development once the patent and ownership issue has been addressed.\n Initial feedback on patients treated prior to Easton purchasing its minority interest in Xilive has been extremely encouraging although they were not performed under the supervision of oncologists in a controlled study. Easton will formalize a clinical plan aimed at \"fast-track\" approval in most controlled jurisdicti...